Fomepizole acts as a competitive inhibitor of alcohol dehydrogenase, thereby preventing the formation of methanol metabolites.[16] Alternatively, ethanol, a competitive substrate for alcohol dehydrogenase, may be administered to inhibit methanol metabolism.[16] Nonetheless, ethanol administration is associated with unpredictable pharmacokinetics and may induce alterations in mental status, hypoglycemia, pancreatitis, and an elevated risk of cardiovascular diseases. The gene discussed is AKR1A1; the disease is cardiovascular disorder.